1
|
Quivoron C, Michot JM, Danu A, Lecourt H, Saada V, Saleh K, Vergé V, Cotteret S, Bernard OA, Ribrag V. Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study. Leuk Lymphoma 2024:1-11. [PMID: 38433500 DOI: 10.1080/10428194.2024.2320258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Accepted: 02/13/2024] [Indexed: 03/05/2024]
Abstract
As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to monitor molecular response and treatment resistance of patients with refractory/relapsed multiple myeloma (R/R MM). We evaluated the sensitivity and specificity of cfDNA compared to BMA CD138 positive myeloma plasma cells (PCs) in a series of 45 R/R MM patients using the 29-gene targeted panel (AmpliSeq) NGS. KRAS, NRAS, FAM46C, DIS3, and TP53 were the most frequently mutated genes. The average sensitivity and specificity of cfDNA detection were 65% and 97%, respectively. The concordance per gene between the two samples was good to excellent according to Cohen's κ coefficients interpretation. An increased number of mutations detected in cfDNA were associated with a decreased overall survival. In conclusion, we demonstrated cfDNA NGS analysis feasibility and accuracy in R/R MM patients who may benefit from early phase clinical trial.
Collapse
Affiliation(s)
- C Quivoron
- Translational Hematology Laboratory, AMMICa, INSERM US23/CNRS UAR3655, Gustave Roussy Cancer Campus, Villejuif, France
- INSERM U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France
| | - J-M Michot
- INSERM U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France
- Drug Development Department: Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France
| | - A Danu
- Hematology Department, Gustave Roussy, Villejuif, France
| | - H Lecourt
- Translational Hematology Laboratory, AMMICa, INSERM US23/CNRS UAR3655, Gustave Roussy Cancer Campus, Villejuif, France
| | - V Saada
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France
| | - K Saleh
- Hematology Department, Gustave Roussy, Villejuif, France
| | - V Vergé
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France
| | - S Cotteret
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France
| | - O A Bernard
- INSERM U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France
| | - V Ribrag
- Translational Hematology Laboratory, AMMICa, INSERM US23/CNRS UAR3655, Gustave Roussy Cancer Campus, Villejuif, France
- INSERM U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France
- Drug Development Department: Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France
- Hematology Department, Gustave Roussy, Villejuif, France
| |
Collapse
|
2
|
Gueiderikh A, Ung M, Lazarovici J, Danu A, Ghez D, Saleh K, Dragani M, Noël N, Bigenwald C, Willekens C, Ribrag V, Michot JM, Martin V. Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases. Cancer Radiother 2023; 27:370-375. [PMID: 37156711 DOI: 10.1016/j.canrad.2023.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 03/30/2023] [Accepted: 04/15/2023] [Indexed: 05/10/2023]
Abstract
PURPOSE Follicular lymphoma (FL) is one of the most common lymphoma. Occasionally, FL is associated with tumoral epidural compression and management of these patients remain poorly codified. This study aims to report incidence, clinical characteristics, management and outcomes of patients with FL and tumoral epidural compression. MATERIAL AND METHODS Observational, retrospective cohort study of adult patients with FL and epidural tumor compression, treated in a French Institute over the last 20 years (2000-2021). RESULTS Between 2000 and 2021, 1382 patients with FL were followed by the haematological department. Of them, 22 (1.6%) patients (16 men and 6 women) had follicular lymphoma with epidural tumor compression. At epidural tumor compression occurrence, 8/22 (36%) patients had a neurological clinical deficit (motor, sensory or sphincter function) and 14/22 (64%) had tumor pain. All patients were treated with immuno-chemotherapy; the main regimen being used was R-CHOP plus high dose IV methotrexate in 16/22 (73%) patients. Radiotherapy for tumor epidural compression was performed in 19/22 (86%) patients. With a median follow-up of 60 months (range=[1-216]), 5 year local tumor relapse free survival was achieved in 65% (95% CI 47-90%) of patients. The median PFS was of 36 months (95% CI 24-NA) and 5 years OS estimate was 79% (95% CI 62-100%). Two patients developed a relapse at a second epidural site. CONCLUSION FL with tumoral epidural compression reached 1.6% of all FL patients. Management based on immuno-chemotherapy with radiotherapy appeared to produce comparable outcomes with the general FL population.
Collapse
Affiliation(s)
- A Gueiderikh
- Radiation therapy department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
| | - M Ung
- Radiation therapy department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - J Lazarovici
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - A Danu
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - D Ghez
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - K Saleh
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - M Dragani
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - N Noël
- Internal medicine department, hôpital Bicêtre, AP-HP, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - C Bigenwald
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - C Willekens
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - V Ribrag
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - J-M Michot
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - V Martin
- Radiation therapy department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| |
Collapse
|
3
|
Valery M, Saleh K, Ecea R, Michot JM, Ribrag V, Fizazi K, Hollebecque A, Lecesne A, Ponce S, Loriot Y, Champiat S, Baldini C, Sarkozy C, Castilla-Llorente C. Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients. Cancer Chemother Pharmacol 2023:10.1007/s00280-023-04551-6. [PMID: 37354233 DOI: 10.1007/s00280-023-04551-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 06/07/2023] [Indexed: 06/26/2023]
Abstract
BACKGROUND Cytokine release syndrome (CRS) is a common adverse event of CAR T cell or bispecific antibody (bsAb) therapy. Anti-IL6/IL6R drugs are used in the management of auto-immune diseases. Some reports showed increased risk of bacterial infection in this context. In onco-hematology, there are few data about the occurrence of infection after administration of an anti-IL6/IL6R for CRS. METHODS We retrospectively reviewed all consecutive patients treated in Gustave Roussy Cancer Campus between 2018 and 2021, who received anti-IL6/IL6R for CRS due to bsAb in phase I clinical trials or adoptive cellular therapy (ACT). We constituted a control group including all the patients treated in the same clinical trials or standard of care ACT, naïve of anti-IL6/IL6R. RESULTS Fifty-two patients have been included. In the anti-IL6/IL6R group (n = 26), five patients developed a grade 2 to 5 infection within a month after anti-IL6/IL6R treatment, including two grade 5 infections. In the control group (n = 26), only one patient had a grade 3 infection. The two patients who had grade 5 infections were treated for diffuse large B cell lymphoma (DLBCL), one with bsAb and the other with CAR T cell. Fifty percent (3/6) of DLBCL patients who received an anti-IL6/IL6R presented an infection, one of which was a grade 5. In solid tumor patients treated with bsAb and anti-IL6/IL6R, only one patient (/9, 11%) developed a grade 2 viral infection. CONCLUSION It seems that the use of anti-IL6/IL6R in CRS secondary to bsAb administration in solid tumors patients does not significantly increase the risk of infection, as opposed to DLBCL patients where secondary infection might be a concern.
Collapse
Affiliation(s)
- M Valery
- Department of Medical Oncology, Gustave Roussy Cancer Campus, 94805, Villejuif, France.
| | - K Saleh
- Department of Hematology, Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - R Ecea
- Department of Medical Oncology, Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - J M Michot
- Département d'Innovation Thérapeutique et d'essais précoces (DITEP), Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - V Ribrag
- Department of Hematology, Gustave Roussy Cancer Campus, 94805, Villejuif, France
- Département d'Innovation Thérapeutique et d'essais précoces (DITEP), Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - K Fizazi
- Department of Medical Oncology, Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - A Hollebecque
- Department of Medical Oncology, Gustave Roussy Cancer Campus, 94805, Villejuif, France
- Département d'Innovation Thérapeutique et d'essais précoces (DITEP), Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - A Lecesne
- International Department, Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - S Ponce
- Département d'Innovation Thérapeutique et d'essais précoces (DITEP), Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - Y Loriot
- Department of Medical Oncology, Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - S Champiat
- Département d'Innovation Thérapeutique et d'essais précoces (DITEP), Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - C Baldini
- Département d'Innovation Thérapeutique et d'essais précoces (DITEP), Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - C Sarkozy
- Department of Hematology, Institut Curie, 92210, Saint-Cloud, France
| | - C Castilla-Llorente
- Department of Hematology, Gustave Roussy Cancer Campus, 94805, Villejuif, France
| |
Collapse
|
4
|
Herbel N, Goldschmidt V, Michot JM, Laparra A, Géraud A, Ouali K, Danlos FX, Martin Romano P, Vuagnat P, Bernard-Tessier A, Gazzah A, Bahleda R, Hollebecque A, Marabelle A, Postel-Vinay S, Massard C, Ribrag V, Ponce Aix S, Champiat S, Baldini C. 86P Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
5
|
Alouani E, Gazzah A, Mercier S, Bahleda R, Hollebecque A, Michot JM, Baldini C, Champiat S, Marabelle A, Postel-Vinay S, Ribrag V, Loriot Y, Ponce S, Mahjoubi L. 461P Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Parisi C, Benitez J, Lecourt H, Dall'Olio F, Aldea M, Blanc-Durand F, Vergé V, Quivoron C, Naltet C, Abdayem P, Lavaud P, Ghigna M, Loriot Y, De Botton S, Planchard D, Barlesi F, Soria JC, Ribrag V, Friboulet L, Besse B. 1198P Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Ribrag V, Davar D, Garralda E, Curigliano G, Zain J, Mehta A, Minchom A, Sanborn R, Foss F, Oberoi H, Forero-Torres A, Ansell S. 558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
8
|
Bayle A, Baldini C, Romano PM, Michot JM, Champiat S, Bahleda R, Gazzah A, Marabelle A, Verlingue L, Geraud A, Morel D, Michiels S, Ribrag V, Hollebecque A, Albiges L, Besse B, Soria JC, Massard C, Barlesi F, Postel-Vinay S. 1617P Sustained cancer clinical trial activity during the COVID-19 pandemic. Ann Oncol 2021. [PMCID: PMC8454374 DOI: 10.1016/j.annonc.2021.08.1610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
9
|
Jurczak W, Zinzani PL, Cunningham D, Yavrom S, Huang W, Gorbatchevsky I, Ribrag V. COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL). Hematol Oncol 2021. [DOI: 10.1002/hon.174_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- W. Jurczak
- Maria Sklodowska‐Curie National Research Institute of Oncology Hematology Krakow Poland
| | - P. L. Zinzani
- Institute of Hematology "L. e A. Seràgnoli" Lymphoma and Chronic Lymphoproliferative Syndromes Unit Bologna Italy
| | - D. Cunningham
- Royal Marsden Hospital NHS Foundation Trust, Haematology‐Oncology London UK
| | - S. Yavrom
- MEI Pharma Inc. Clinical Development San Diego USA
| | - W. Huang
- MEI Pharma Inc. Biostats San Diego USA
| | | | - V. Ribrag
- Institut Gustave Roussy Hematology Villejuif France
| |
Collapse
|
10
|
Batlevi CL, Salles G, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Campbell P, Ribrag V, Damaj GL, Dickinson M, Jurczak W, Kaźmierczak M, Opat S, Radford JR, Schmitt A, Rajarethinam A, Shang G, Morschhauser F. CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL). Hematol Oncol 2021. [DOI: 10.1002/hon.21_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- C. L. Batlevi
- Memorial Sloan Kettering Cancer Center Lymphoma Service Department of Medicine New York USA
| | - G. Salles
- Lyon‐Sud Hospital University of Lyon Hematology Pierre‐Bénite France
| | - H. Tilly
- Centre Henri Becquerel and Rouen University Department of Haematology and INSERM U1245 Rouen France
| | - A. Chaidos
- Imperial College Healthcare NHS Trust Hammersmith Hospital Department of Medicine London UK
| | - P. McKay
- Beatson West of Scotland Cancer Centre Department of Hematology Glasgow UK
| | - T. Phillips
- University of Michigan Hematology and Oncology Ann Arbor USA
| | - S. Assouline
- Division of Hematology Sir Mortimer B. Davis‐Jewish General Hospital Oncology Montreal Canada
| | - P. Campbell
- Barwon Health University Hospital Geelong Department of Clinical Haematology Geelong Australia
| | - V. Ribrag
- Gustave Roussy Hematology Villejuif France
| | - G. Laurent Damaj
- Hematology Institute University Hospital School of Medicine Hematology Caen France
| | - M. Dickinson
- Peter MacCallum Cancer Centre Royal Melbourne Hospital Department of Clinical Haematology Melbourne Australia
| | - W. Jurczak
- Maria Sklodowska‐Curie National Research Institute of Oncology Department of Hematology Kraków Poland
| | - M. Kaźmierczak
- Poznań University of Medical Sciences Department of Hematology and Bone Marrow Transplantation Poznań Poland
| | - S. Opat
- Monash University Department of Haematology Victoria Australia
| | - J. R. Radford
- University of Manchester NIHR Manchester Clinical Research Facility Manchester Academic Health Science Centre The Christie NHS Foundation Trust Department of Medical Oncology Manchester UK
| | - A. Schmitt
- Institut Bergonié Department of Hematology Bordeaux France
| | | | - G. Shang
- Epizyme, Inc. Medical Affairs Cambridge USA
| | - F. Morschhauser
- Groupe de Recherche sur les formes Injectables et les Technologies Associées CHU de Lille Université de Lille Oncology Lille France
| |
Collapse
|
11
|
Bologna S, Vander Borght T, Briere J, Ribrag V, Damaj GL, Thieblemont C, Feugier P, Peyrade F, Lebras L, Coso D, Sibon D, Bonnet C, Morschhauser F, Ghesquieres H, Becker S, Olivier P, Fabiani B, Tilly H, Haioun C, Bastie JN. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.5_2879] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S Bologna
- Hématologie Privée Nancéienne 54 Essey lès Nancy France
| | | | - J Briere
- CHU Henri Mondor 94 Créteil France
| | - V Ribrag
- Institut Gustave Roussy 94 Villejuif France
| | | | | | - P Feugier
- CHRU Nancy 54 Vandoeuvre lès Nancy France
| | - F Peyrade
- Centre Antoine Lacassagne 06 Nice France
| | - L Lebras
- Centre Léon Berard 69 Lyon, France
| | - D Coso
- Institut Paoli Calmette 13 Marseille France
| | - D Sibon
- Hôpital Necker-Enfants Malades 75 Paris France
| | | | | | | | - S Becker
- Centre Henri Becquerel 76 Rouen France
| | - P Olivier
- CHRU Nancy 54 Vandoeuvre lès Nancy France
| | - B Fabiani
- Hopital Saint Antoine 75 Paris France
| | - H Tilly
- Centre Henry Becquerel 76 Rouen France
| | - C Haioun
- Hopital Henri Mondor 94 Créteil France
| | | |
Collapse
|
12
|
Cheminant M, Burroni B, Bris Y, Chartier L, Oberic L, Ribrag V, Delfau M, Thieblemont C, Gressin R, Canioni D, Peyre M, Laurent C, Steimle T, Kaltenbach S, Asnafi V, Macintyre E, Callanan M, Gouill S, Hermine O. HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.64_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Cheminant
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - B. Burroni
- Cochin University Hospital Pathology Paris France
| | - Y. Bris
- Nantes University Hospital Hematolobiology Nantes France
| | | | - L. Oberic
- Toulouse‐Oncopole University hospital Hematology Toulouse France
| | - V. Ribrag
- Gustave‐Roussy Hematology Villejuif France
| | - M.‐H. Delfau
- Mondor University Hospital Hematolobiology Créteil France
| | | | - R. Gressin
- Grenoble University Hospital Hematology Grenoble France
| | - D. Canioni
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - M. Peyre
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | | | - T. Steimle
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - S. Kaltenbach
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - V. Asnafi
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - E. Macintyre
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| | - M. Callanan
- Dijon University Hospital Hematobiology Dijon France
| | - S. Gouill
- Nantes University Hospital Hematology Nantes France
| | - O. Hermine
- Necker‐Enfants Malades University Hospital Adult Hematology 75015 France
| |
Collapse
|
13
|
Paunescu A, Paget J, Bergman CC, Malak S, Le Gouill S, Ribrag V, Bouabdallah K, Sibon D, Rumpold G, Preau M, Mounier N, Haioun C, Jardin F, Besson C. GENDER DISPARITIES IN QUALITY OF LIFE OF FRENCH PATIENTS ONE YEAR AFTER THE DIAGNOSIS OF LYMPHOMA. A LYSA STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.192_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | | | | | - S. Malak
- Curie Hematology Saint‐Cloud France
| | | | - V. Ribrag
- Gustave Roussy Hematology Villejuif France
| | | | - D. Sibon
- CHU Necker, Hematology Paris France
| | - G. Rumpold
- Medical University Innsbruck Department of Medical Psychology Innsbruck Austria
| | - M. Preau
- Université Lyon 2 GRePS Lyon France
| | | | - C. Haioun
- Henri Mondor University Hospital Lymphoid malignancies unit Créteil France
| | - F. Jardin
- Centre Henri Becquerel Hematology Rouen France
| | - C. Besson
- CH Versailles, Hematology Le Chesnay France
| |
Collapse
|
14
|
Bohers E, Delfau‐Larue M, Vercellino L, Cottereau A, Viennot M, Viailly P, Salles G, Tilly H, Damaj G, Haioun C, Ribrag V, Morschhauser F, Casasnovas R, Nicolas‐Virelizier E, Feugier P, Bouabdallah R, Cartron G, Renaud L, Chartier L, Portugues C, Meignan M, Jardin F, Thieblemont C. CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.3_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- E Bohers
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors INSERM U1245, Normandy University Rouen France
| | - M Delfau‐Larue
- Hematobiology and Immunobiology Department INSERM U955 Eq9, APHP University Hospital Henri Mondor Créteil France
| | - L Vercellino
- Department of Nuclear C, APHP Saint‐Louis Hospital Paris France
| | - A Cottereau
- Department of Nuclear Medicine APHP, Cochin Paris France
| | - M Viennot
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors INSERM U1245, Normandy University Rouen France
| | - P Viailly
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors INSERM U1245, Normandy University Rouen France
| | - G Salles
- Memorial Sloan Kettering Cancer Center Lymphoma Department New York New York USA
| | - H Tilly
- Department of Hematology Henri Becquerel Center Rouen France
| | - G Damaj
- Department of Hematology Caen University Hospital Caen France
| | - C Haioun
- Department of Hematology Henri Mondor University Hospital Créteil France
| | - V Ribrag
- Department of Hematology Gustave Roussy Institute Villejuif France
| | - F Morschhauser
- Department of Hematology Lille University Hospital Lille France
| | - R Casasnovas
- Department of Hematology Dijon University Hospital Dijon France
| | | | - P Feugier
- Department of Hematology Nancy university Hospital Vandoeuvre‐les‐Nancy France
| | - R Bouabdallah
- Department of Hematology Paoli Calmette Institute Marseille France
| | - G Cartron
- Department of Hematology Montpellier University Hospital Montpellier France
| | - L Renaud
- Department of Hematology Lille University Hospital Lille France
| | - L Chartier
- LYSARC, Lyon Hospital Pierre‐Benite France
| | | | - M Meignan
- Department of Nuclear Medicine APHP, University Hospital Henri Mondor Creteil France
| | - F Jardin
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors INSERM U1245, Normandy University Rouen France
| | - C Thieblemont
- Department of Hematology APHP, Saint‐Louis Hospital Paris France
| |
Collapse
|
15
|
Procureur A, Bizot A, Michot JM, Ammari S, Verlingue L, Baldini C, Martin-Romano P, Ribrag V, Soria JC, Massard C, Postel-Vinay S. 9P Predictive factors and profiles of tumour response to epigenetic drugs in phase I trials. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.01.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
16
|
Michot JM, Camara-Clayette V, Quivoron C, Danu A, Lazarovici J, Ghez D, Rossignol J, Baldini C, Martin Romano P, Sarkozy C, Varga A, Cotteret S, Dartigues P, Massard C, Ribrag V. 24P Is molecular characterization useful for targeted therapy orientation in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) included in early phase clinical trials? Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
17
|
Baldini C, Romano P, Vincent H, Vuagnat P, Champiat S, Michot J, Bahleda R, Gazzah A, Vinay S, Hollebecque A, Angevin E, Ribrag V, Loriot Y, Marabelle A, Massard C, Varga A. SAFETY PROFILE OF COMBINATION THERAPY WITH IMMUNE CHECKPOINT BLOCKERS AND VEGF INHIBITORS IN OLDER PATIENTS TREATED IN EARLY PHASE CLINICAL TRIALS. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31299-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V, Lambotte O. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 2019; 122:72-90. [PMID: 31634647 DOI: 10.1016/j.ejca.2019.07.014] [Citation(s) in RCA: 75] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2019] [Revised: 07/21/2019] [Accepted: 07/23/2019] [Indexed: 01/06/2023]
Abstract
Immune checkpoint inhibitors (ICIs) are changing the treatments of many patients with cancer. These immunotherapies are generally better tolerated than chemotherapy, and their adverse events are immune-related mimicking autoimmune or inflammatory conditions. Although these immune-related adverse events mainly affect the skin, endocrine glands, digestive tract, joints, liver or lungs, all the organs can be theoretically affected, and the haematopoietic system is not spared. This review of the literature will focus on the haematological immune-related adverse events (Haem-irAEs). By reviewing the largest clinical trials of ICIs, we estimate the frequency of Haem-irAEs at 3.6% for all grades and 0.7% for grades III-IV. Frequency of Haem-irAEs of all grades was found to be higher with anti-programmed cell death 1 (4.1%) or anti-programmed cell death ligand 1 (4.7%) than with anti-cytotoxic T-lymphocyte-associated protein 4 (0.5%) (p < 0.0001). From the 63 cases with Haem-irAEs reported in the literature, the mean time to the onset was found to be 10 weeks after ICI initiation, and the large range for occurrence (1-84 weeks) and the regular incidence suggest that Haem-irAEs could occur at any time after ICI therapy. Among the 63 reported cases with Haem-irAEs, the distribution was immune thrombocytopenia (n = 18, 29%), pancytopenia or immune aplastic anaemia (n = 12, 19%), neutropenia (n = 11, 17%), haemolytic anaemia (n = 10, 16%), cytokine release syndrome with haemophagocytic syndrome (n = 7, 11%) and other Haem-irAEs including bicytopenia or pure red cell aplasia (n = 5, 8%). Haem-irAEs are generally highly severe adverse reactions with a mortality rate of Haem-irAEs reported to be 14% (9 deaths among the 63 cases reported). The more severe and life-threatening Haem-irAEs were both cytokine release syndrome with haemophagocytic syndrome and pancytopenia or aplastic anaemia. Haem-irAEs induced by ICIs are potentially life-threatening. By discussing their pathophysiological aspects and clinical picture, we propose in this review clinical guidelines for management.
Collapse
Affiliation(s)
- J M Michot
- Gustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif, F-94805, France; Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Médecine Interne et Immunologie Clinique, Le Kremlin-Bicêtre, F-94275, France.
| | - J Lazarovici
- Gustave Roussy, Université Paris-Saclay, Département D'Hématologie, Villejuif, F-94805, France
| | - A Tieu
- Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Médecine Interne et Immunologie Clinique, Le Kremlin-Bicêtre, F-94275, France
| | - S Champiat
- Gustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif, F-94805, France
| | - A L Voisin
- Gustave Roussy, Université Paris-Saclay, Unité de Pharmacovigilance, Villejuif, F-94805, France
| | - M Ebbo
- Assistance Publique - Hôpitaux de Marseille, Hôpital de La Timone, Médecine Interne, Marseille, F-13005, France
| | - B Godeau
- Assistance Publique - Hôpitaux de Paris, Hôpital Henri Mondor, Médecine Interne, Centre de Référence des Cytopénies Auto-immunes de L'Adulte, Université Paris-Est Créteil, Créteil, F-94010, France
| | - M Michel
- Assistance Publique - Hôpitaux de Paris, Hôpital Henri Mondor, Médecine Interne, Centre de Référence des Cytopénies Auto-immunes de L'Adulte, Université Paris-Est Créteil, Créteil, F-94010, France
| | - V Ribrag
- Gustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif, F-94805, France; Gustave Roussy, Université Paris-Saclay, Département D'Hématologie, Villejuif, F-94805, France
| | - O Lambotte
- Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Médecine Interne et Immunologie Clinique, Le Kremlin-Bicêtre, F-94275, France; INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre, F-94276, France; Université Paris Sud, UMR 1184, Le Kremlin-Bicêtre, F-94276, France; CEA, DSV/iMETI, IDMIT, Fontenay-aux-Roses, F-92265, France
| |
Collapse
|
19
|
Boulfoul W, Baldini C, Borget I, Martin Romano P, Verlingue L, Lacroix L, Angevin E, Rouleau E, Varga A, Postel Vinay S, Gazzah A, Bahleda R, Marabelle A, Ribrag V, Vuagnat P, Champiat S, Michot JM, Hollebecque A, Soria JC, Massard C. Precision medicine for patients with primary brain tumours: Molecular screening for cancer treatment optimization (MOSCATO) prospective trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz243.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Bizot A, Romano-Martin P, Baldini C, Champiat S, Varga A, Gazzah A, Bahleda R, Vuagnat P, Hollebecque A, Michot JM, Ribrag V, Massard C, Vinay SP. Are epigenetic therapies modifying sensitivity to conventional chemotherapy? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Baldini C, Boulfoul W, Lacroix L, Rouleau E, Scoazec J, Varga A, Hollebecque A, Ribrag V, Soria J, Massard C. P13.14 Use of Foundation one CDx for molecular screening in patients with primary brain tumors: Gustave Roussy Experience. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Patients with primary brain tumors usually have poor prognosis and few therapeutic options. However recent report showed that they may benefit from molecular screening to improve treatment benefit and enrollment in clinical trials. We aimed to evaluate if molecular screening using Foundation One Dx may help therapeutic strategies in primary brain tumor patients.
MATERIAL AND METHODS
Between October 2018 and December 2018, we enrolled prospectively patients in the MOSCATO (Molecular Screening for cancer Treatment Optimization) 02 trial using the Foundation One Dx test. Patients were eligible if they had good Performans status (PS) (0 or 1) and tumor tissue material available. Results were reviewed during a molecular multidisciplinary meeting weekly at the Drug Development Department at Gustave Roussy to decide on orientation and matched therapy according to molecular alterations.
RESULTS
Finally thirty-three patients were enrolled in the study. Twenty six tumor tissues were analysed and 7 patients were screen failures due to tumor tissue unavailability. Median age was 49 years old (19 - 72). Patients had a good PS with a median of 1 (0–2) and were mostly males (76%). The most common tumor type was glioblastoma (79%). Five patients had a high grade tumor including 2 medulloblastomas. Median time between consent and multidisciplinary meeting was 70 days (49 - 156). Median percentage of tumor cells was 78% (30–80%). The tumor mutational burden (TMB) was available in 26 patients. The median TMB was 4 mutations per megabase (0 - 277). The most frequent alterations were TERT promoter mutation 22/26 (85%), CDKN2A loss 14/26 (54%), MTAP loss 11/26 (42%), EGFR amplification (38%) including 4 EGFRvIII amplification, TP53 mutation and PTEN deletion 9/26 (35%) respectively, PIK3CA mutation 5/26 (19%), CDK4 or 6 amplification 4/26 (15%), NF1 mutation 3/26 (12%), 2 IDH1 mutations, 2 MET amplifications, 2 HGF amplifications, 1 FGFR2 mutation, 1 BRAF V600E mutation, 1 PDGFRA amplification, 1 EZH2 mutation and 1 SMARCA4 mutation. Finally 11 patients (42%) were oriented according to molecular alterations (EGFR amplifications, BRAF mutation), 1 patient was treated and is ongoing with a BRAF inhibitor and 1 patient is in screening in atrial with an EGFR inhibitor.
CONCLUSION
Molecular screening with Foundation One Dx test is feasible in patients with primary brain tumors and can help therapeutic strategies. However the time between consent and multidisciplinary meeting was the main limitation to our study and affected enrollment in clinical trials.
Collapse
Affiliation(s)
| | | | | | | | | | - A Varga
- Gustave Roussy, Villejuif, France
| | | | - V Ribrag
- Gustave Roussy, Villejuif, France
| | - J Soria
- Gustave Roussy, Villejuif, France
| | | |
Collapse
|
22
|
Okosun J, Bödör C, Batlevi C, Nagy N, Michot J, Schneider T, Alizadeh H, Simon Z, Vose J, Younes A, Ribrag V, Fitzgibbon J, Yang J, Agarwal S, Newberry K, Michaud N. EZH2 GAIN-OF-FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.6_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Okosun
- Hematology, Barts Cancer Institute; Queen Mary University of London; London United Kingdom
| | - C. Bödör
- Hematology; Semmelweis University; Budapest Hungary
| | - C. Batlevi
- Medical Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - N. Nagy
- Cancer Research; Semmelweis University; Budapest Hungary
| | - J. Michot
- Hematology and Innovative Drugs; Gustave Roussy; Villejuif France
| | - T. Schneider
- Medical Oncology and Hematology; National Institute of Oncology; Budapest Hungary
| | - H. Alizadeh
- Internal Medicine; University of Pecs; Pecs Hungary
| | - Z. Simon
- Biochemistry and Molecular Biology; University of Debrecen; Debrecen Hungary
| | - J. Vose
- Oncology & Hematology; University of Nebraska Medical Center; Omaha United States
| | - A. Younes
- Medical Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - V. Ribrag
- DITEP; Gustave Roussy; Villejuif France
| | - J. Fitzgibbon
- Hematology, Barts Cancer Institute; Queen Mary University of London; London United Kingdom
| | - J. Yang
- Biostatistics; Epizyme; Cambridge United States
| | - S. Agarwal
- Chief Medical Officer; Epizyme; Cambridge United States
| | | | - N.R. Michaud
- Translational Medicine; Epizyme; Cambridge United States
| |
Collapse
|
23
|
Morschhauser F, Tilly H, Chaidos A, Phillips T, Ribrag V, Campbell P, Ghandi Laurent D, Jurczak W, McKay P, Opat S, Radford J, Rajarethinam A, Yang J, Howell H, Newberry K, Adib D, Salles G. INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.111_2629] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- F. Morschhauser
- Hematology-Transfusion; Centre Hospitalier Universitaire; Lille France
| | - H. Tilly
- Hematology; Centre de Lutte Contre le Cancer Henri Becquerel; Rouen France
| | - A. Chaidos
- Medicine, Centre for Haematology, Department of Medicine, Imperial College London, Imperial College Healthcare NHS Trust; Hammersmith Hospital; London United Kingdom
| | - T. Phillips
- Hematology and Oncology; University of Michigan; Ann Arbor United States
| | - V. Ribrag
- DITEP; Gustave Roussy; Villejuif France
| | - P. Campbell
- Hematology; Barwon Health; Geelong Australia
| | - D. Ghandi Laurent
- Hematology; Hematology Institute University Hospital School of Medicine; Caen France
| | | | - P. McKay
- Hematology; Beatson West of Scotland Cancer Centre; Glasgow United Kingdom
| | - S. Opat
- Hematology; Monash University; Clayton Australia
| | - J. Radford
- Medical Oncology; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester United Kingdom
| | | | - J. Yang
- Biostatistics; Epizyme; Cambridge United States
| | - H. Howell
- Clinical Operations; Epizyme; Cambridge United States
| | | | - D. Adib
- Clinical Development; Epizyme; Cambridge United States
| | - G. Salles
- Hematology; Lyon-Sud Hospital Centre; Pierre-Bénite France
| |
Collapse
|
24
|
Palomba M, Cartron G, Popplewell L, Ribrag V, Westin J, Chitra S, Huw L, Newberry K, Raval A, Xu J, Morschhauser F. SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.203_2631] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M.L. Palomba
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - G. Cartron
- Department of Clinical Hematology; CHU Montpellier; Montpellier France
| | - L. Popplewell
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope Comprehensive Cancer Center; Duarte CA United States
| | - V. Ribrag
- DITEP; Gustave Roussy Cancer Campus; Villejuif France
| | - J. Westin
- Department of Lymphoma/Myeloma; MD Anderson Cancer Center; Houston TX United States
| | - S. Chitra
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - L. Huw
- Oncology Biomarker Development; Genentech, Inc.; South San Francisco CA United States
| | - K. Newberry
- Clinical Development; Epizyme; Cambridge MA United States
| | - A. Raval
- Oncology Biomarker Development; Genentech, Inc.; South San Francisco CA United States
| | - J. Xu
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - F. Morschhauser
- Institute of Hematology - Transfusion; Centre Hospitalier Régional Universitaire de Lille; Lille France
| |
Collapse
|
25
|
Cottereau A, Vercellino L, Casasnovas O, Tilly H, Feugier P, Fruchart C, Roulin L, Oberic L, Pica G, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban C, Lopez A, Macro M, Sahnes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Copie-Bergman C, Briere J, Salles G, Gaulard P, Meignan M, Thieblemont C. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.19_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - L. Vercellino
- Medecine Nucleaire; APHP, Saint-Louis Hospital; Paris France
| | | | - H. Tilly
- Hematology; Centre H. Becquerel; Rouen France
| | - P. Feugier
- Hematology; CHU Brabois - Nancy; Nancy France
| | | | - L. Roulin
- Hematology; APHP, Henri Mondor Hospital; Créteil France
| | - L. Oberic
- Hematology; CHU Toulouse; Toulouse France
| | - G. Pica
- Hematology; CHU Annecy; Annecy France
| | | | | | - M. Simon
- Hematology; CH Valenciennes; Valenciennes France
| | | | | | - O. Fitoussi
- Hematology; Hopital Bordeaux Nord; Bordeaux France
| | - C. Sebban
- Hematology; Centre L. Berard; Lyon France
| | - A. Lopez
- Hematology; IOB; Barcelona Spain
| | - M. Macro
- Hematology; CHU Caen; Caen France
| | - L. Sahnes
- Hematology; CH Perpignan; Perpignan France
| | | | - J. Trotman
- Hematology; Concord Hospital; Sydney Australia
| | | | - B. Choufi
- Hematology; CH Boulogne; Boulogne France
| | | | - P. Godmer
- Hematology; CH Vannes; Vannes France
| | | | - J. Briere
- Pathology; APHP, Saint-Louis Hospital; Paris France
| | - G. Salles
- Hematology; CHU Lyon; Pierre-Benite France
| | - P. Gaulard
- Pathology; APHP, Henri Mondor Hospital; Créteil France
| | - M. Meignan
- Medecine Nucleaire; APHP, Henri Mondor Hospital; Créteil France
| | | |
Collapse
|
26
|
Zelenetz A, Zinzani P, Buske C, Ribrag V, Cunningham D, Jurczak W, Abrisqueta P, Agajanian R, Chaudhry A, Kayyal T, Wood J, Llorin-Sangalang J, Brown J. A PIVOTAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM, PHASE 2 STUDY OF ME-401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES. Hematol Oncol 2019. [DOI: 10.1002/hon.2_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Zelenetz
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York United States
| | - P. Zinzani
- Institute of Hematology; University of Bologna; Bologna Italy
| | - C. Buske
- Life Science Gebaeude; Universitatklinikum Ulm; Ulm Germany
| | - V. Ribrag
- Gustave Roussy Cancer Center; Institut Gustave Roussy; Villejuif France
| | - D. Cunningham
- Lymphoma Unit; Royal Marsden Hospital NHS; Sutton United Kingdom
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - P. Abrisqueta
- Department of Hematology; Hospital Vall Hebron; Barcelona Spain
| | - R. Agajanian
- Department of Hematology; The Oncology Institute of Hope and Innovation; Cerritos United States
| | - A. Chaudhry
- Medical Oncology/Hematology; Medical Oncology Associates PS; Spokane United States
| | - T. Kayyal
- Department of Oncology/Hematology; Renovatio Clinical; The Woodlands United States
| | - J. Wood
- Medical Affairs; MEI Pharma, Inc.; San Diego United States
| | | | - J. Brown
- Division of Hematologic Malignancies; Dana Farber Cancer Institute; Boston United States
| |
Collapse
|
27
|
Le Gouill S, Beldi-Ferchiou A, Cacheux V, Salles G, Canioni D, Bodet-Milin C, Alcantara M, Delwail V, Gastinne T, Thieblemont C, Maisonneuve H, Lamy de la Chapelle T, Oberic L, Bouabdallah K, Ribrag V, Delfau-Larue M, Macintyre E, Hermine O. OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA-101 TRIAL, A LYSA GROUP STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.14_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - V. Cacheux
- Hematologie; CHU Clermont-Ferrand; Clermont-Ferrand France
| | | | | | | | | | - V. Delwail
- Hematology Biology; CHU Poitiers; Poitiers France
| | | | | | - H. Maisonneuve
- Hematology-Oncology; CH Roche-Sur-Yon; Roche-Sur-Yon France
| | | | - l. Oberic
- Hematology; Oncopole de Toulouse; Toulouse France
| | | | - V. Ribrag
- Hematology; Institut Gustave Roussy; Villejuif France
| | | | - E. Macintyre
- Hématologie Biologique; Hôpital Necker; Paris France
| | - O. Hermine
- Hematologie; Hôpital Necker; Paris France
| |
Collapse
|
28
|
Michot J, Camara-Clayette V, Detolle A, Chahine C, Lazarovici J, Danu A, Bosq J, Ghez D, Romano-Martin P, Dartigues P, Arfi-Rouche J, Bahleda R, Rahali W, Varga A, Baldini C, Tselikas L, Paume C, Lecourt H, Cotteret S, Vergé V, Soria J, Massard C, Ribrag V. FEASIBILITY AND BENEFIT OF MOLECULARLY-INFORMED ENROLLMENT INTO EARLY PHASE CLINICAL TRIALS FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.142_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- J. Michot
- Hematology; Gustave Roussy; Villejuif France
| | | | - A. Detolle
- Hematology; Gustave Roussy; Villejuif France
| | - C. Chahine
- Hematology; Gustave Roussy; Villejuif France
| | | | - A. Danu
- Hematology; Gustave Roussy; Villejuif France
| | - J. Bosq
- Hematology; Gustave Roussy; Villejuif France
| | - D. Ghez
- Hematology; Gustave Roussy; Villejuif France
| | | | | | | | - R. Bahleda
- Hematology; Gustave Roussy; Villejuif France
| | - W. Rahali
- Hematology; Gustave Roussy; Villejuif France
| | - A. Varga
- Drug Development Department; Gustave Roussy; Villejuif France
| | - C. Baldini
- Drug Development Department; Gustave Roussy; Villejuif France
| | - L. Tselikas
- Drug Development Department; Gustave Roussy; Villejuif France
| | - C. Paume
- Drug Development Department; Gustave Roussy; Villejuif France
| | - H. Lecourt
- Drug Development Department; Gustave Roussy; Villejuif France
| | - S. Cotteret
- Hematology; Gustave Roussy; Villejuif France
| | - V. Vergé
- Hematology; Gustave Roussy; Villejuif France
| | - J. Soria
- Drug Development Department; Gustave Roussy; Villejuif France
| | - C. Massard
- Drug Development Department; Gustave Roussy; Villejuif France
| | - V. Ribrag
- Hematology; Gustave Roussy; Villejuif France
| |
Collapse
|
29
|
Mollaret E, Gomez E, Nadel B, Naiglin L, Anquetin M, Barau C, Baseggio L, Bret C, Brisou G, Brousset P, Camara-Clayette V, Cartron G, Da Cunha K, Dartigues P, Dupuis J, Ghaleh B, Gravelle P, Houot R, Karmous-Gadacha O, Laurent C, Moreaux J, Pangault C, Ribrag V, Salles G, Szablewski V, Thouault V, Uze G, Verge V, Ysebaert L, Gaulard P, Fest T. CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD. Hematol Oncol 2019. [DOI: 10.1002/hon.38_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- E. Mollaret
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - E. Gomez
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - B. Nadel
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - L. Naiglin
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - M. Anquetin
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - C. Barau
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - L. Baseggio
- Laboratoire d'Hématologie; Groupement Hospitalier Sud/Hospices Civils de Lyon; Pierre-Bénite France
| | - C. Bret
- Hématologie Biologique; CHU Montpellier; Montpellier France
| | - G. Brisou
- Hématologie Clinique; Groupement Hospitalier Sud/ Hospices Civils de Lyon; Pierre-Bénite France
| | - P. Brousset
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - V. Camara-Clayette
- Laboratoire RT Hématologie (AMMICa INSERM US23/CNRS UMS3655); Gustave Roussy; Villejuif France
| | - G. Cartron
- Département d'Hématologie Clinique; CHU Montpellier; Montpellier France
| | - K. Da Cunha
- CRB Sud; Groupement Hospitalier Sud/ Hospices Civils de Lyon; Pierre-Bénite France
| | - P. Dartigues
- Département de Biologie et Pathologie Médicales - Service de pathologie Morphologique; Gustave Roussy; Villejuif France
| | - J. Dupuis
- Unité Hémopathies Lymphoïdes; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - B. Ghaleh
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - P. Gravelle
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - R. Houot
- Hématologie; CHU Rennes - Pontchaillou; RENNES France
| | | | - C. Laurent
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - J. Moreaux
- Hématologie Biologique; CHU Montpellier; Montpellier France
| | - C. Pangault
- UMR-S 1236 / Laboratoire Hématologie; Université de Rennes I / CHU Rennes; Rennes France
| | - V. Ribrag
- Laboratoire RT Hématologie (AMMICa INSERM US23/CNRS UMS3655); Gustave Roussy; Villejuif France
| | - G. Salles
- Hématologie Clinique; Hospices Civils de Lyon / Université Claude Bernard; Pierre Bénite France
| | - V. Szablewski
- Pathologie et Oncobiologie; CHU Montpellier; Montpellier France
| | - V. Thouault
- Laboratoire d'hématologie; CHU Rennes - Pontchaillou; Rennes France
| | - G. Uze
- UMR 5235; CNRS / University Montpellier; Montpellier France
| | - V. Verge
- Département de Biologie et Pathologie Médicales - Laboratoire d'hématologie; Gustave Roussy; Villejuif France
| | - L. Ysebaert
- Hématologie; IUC-Toulouse Oncopole; Toulouse France
| | - P. Gaulard
- Department of Pathology; AP-HP; Créteil France
| | - T. Fest
- UMR-S 1236 / Laboratoire Hématologie; Université de Rennes I / CHU Rennes; Rennes France
| |
Collapse
|
30
|
Zinzani P, Armand P, Ribrag V, Michot J, Kuruvilla J, Zhu Y, Farooqui M, Nahar A, Moskowitz C. PHASE 1B KEYNOTE-013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW-UP. Hematol Oncol 2019. [DOI: 10.1002/hon.106_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P.L. Zinzani
- Oncology; Institute of Hematology, University of Bologna; Bologna Italy
| | - P. Armand
- Medical Oncology; Dana-Farber Cancer Institute, Boston; United States
| | - V. Ribrag
- Medical Oncology; Institut Gustave Roussy, Villejuif; France
| | - J. Michot
- Medical Oncology; Institut Gustave Roussy, Villejuif; France
| | - J. Kuruvilla
- Medical Oncology and Hematology; Princess Margaret Cancer Centre and University of Toronto; Toronto Canada
| | - Y. Zhu
- Medical Oncology; Merck & Co, Inc.; Kenilworth United States
| | - M. Farooqui
- Medical Oncology; Merck & Co, Inc.; Kenilworth United States
| | - A. Nahar
- Medical Oncology; Merck & Co, Inc.; Kenilworth United States
| | - C.H. Moskowitz
- Medicine; University of Miami Sylvester Comprehensive Cancer Center; Miami United States
| |
Collapse
|
31
|
Delfau-Larue M, Boulland M, Feugier P, Maisonneuve H, Casasnovas O, Haioun C, Pica G, Lamy de la Chapelle T, Ysebaert L, Tilly H, Eisenmann J, Le Gouil S, Ribrag V, Jardel H, Glaisner S, Cartron G, Salles G, Xerri L, Fest T, Morschhauser F. RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.77_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M.H. Delfau-Larue
- Biological Hematology and Immunology Department; U955 Eq9, APHP, Groupe Hospitalier Mondor; Creteil France
| | - M.L. Boulland
- Hematobiology department; CHU Pontchaillou; Rennes France
| | - P. Feugier
- Service d'Hématologie; CHRU de Nancy; Vandoeuvre les Nancy France
| | - H. Maisonneuve
- Service d'Onco-Hématologie; CHD Vendée; La Roche-sur-Yon France
| | - O. Casasnovas
- Service d'Hématologie Clinique; CHU Le Bocage; Dijon France
| | - C. Haioun
- Unité Hémopathies Lymphoïdes; University hospital Mondor; Creteil France
| | - G.M. Pica
- Service Hématologie; CH Métropole Savoie; Chambéry France
| | | | - L. Ysebaert
- Service d'Hématologie; IUCT Oncopole; Toulouse France
| | - H. Tilly
- U1245 and Département d'Hématologie; Centre Henri Becquerel; Rouen France
| | - J.C. Eisenmann
- Département d'Hématologie; CH de Mulhouse; Hôp Emile Muller Mulhouse France
| | - S. Le Gouil
- Service d'Hématologie Clinique; CHU de Nantes - Hôtel Dieu; Nantes France
| | - V. Ribrag
- Hematology Department; Gustave Roussy Cancer Campus Grand Paris; Villejuif France
| | - H. Jardel
- Service Hématologie; Centre Hospitalier Bretagne-Atlantique; Vannes France
| | - S. Glaisner
- Service d'Hématologie; Centre René Huguenin; Saint-Cloud France
| | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | - G. Salles
- Département d'Hématologie; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud; Lyon France
| | - L. Xerri
- Departement de Bio-pathologie; Institut Paoli-Calmettes; Marseille France
| | - T. Fest
- Hematobiology department; CHU Pontchaillou; Rennes France
| | | |
Collapse
|
32
|
Leroy L, Satar T, Baldini C, Martin-Romano P, Hollebecque A, Michot JM, Ribrag V, Massard C, Paoletti X, Postel Vinay S. Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz029.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Vuagnat P, Baldini C, Verlingue L, Martin Romano P, Varga A, Hollebecque A, Postel-Vinay S, Gazzah A, Bahleda R, Marabelle A, Ribrag V, Champiat S, Michot JM, Soria JC, Massard C. Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Bernard-Tessier A, Baldini C, Castanon Alvarez E, Ammari S, Martin Romano P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C. Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Baldini C, Martin-Romano P, Voisin AL, Danlos F, Champiat S, Laghouati S, Kfouri M, Vincent H, Nagera C, Postel-Vinay S, Varga A, Ribrag V, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A. Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.079] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Abdelshafy M, El Dakdouki Y, Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, Balheda R, Michot JM, Marabelle A, Rouleau E, Solary E, de Baere T, Angevin E, Ribrag V, Michiels S, André F, Scoazec JY, Soria JC, Massard C. Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Vozy A, Simonaggio A, Auclin E, Mezquita L, Baldini C, Martin-Romano P, Pistilli B, Gazzah A, Bahleda R, Ribrag V, Postel-Vinay S, Champiat S, Soria JC, André F, Massard C, Besse B, Delaloge S, Varga A. Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.286] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Boros A, Ribrag V, Deutsch É, Chargari C, Izar F. [Radiation therapy planning for Hodgkin lymphoma: Focus on intensity-modulated radiotherapy, gating, protons. Which techniques to best deliver radiation?]. Cancer Radiother 2018; 22:404-410. [PMID: 30076071 DOI: 10.1016/j.canrad.2018.07.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Accepted: 06/21/2018] [Indexed: 11/28/2022]
Abstract
The optimization of radiotherapy in these young and long-lived survivors raises the question about the interest of using modern techniques to allow a better distribution of the dose. The choice of the irradiation technique must take into account the incidence of side effects related to radiation. In this context, the definition of the target volumes as well as the verification and monitoring of the delivered processing are essential. International recommendations for treatment fields are based on the "involved node radiotherapy" concept. The best irradiation technique to use remains to be defined. The use of intensity-modulated radiotherapy improves the coverage and reduces the dose to the organs at risk with a variable gain depending on the topography of the lymph nodes: upper or lower mediastinum, right or left lateralization, the techniques used. The deep inspiration breath-hold technique allows an increase of the pulmonary volume, extension of the mediastinum with an up down of the heart which make possible to move the planning target volume away from the cardiac structures. The volumetric-modulated arctherapy technique with several arches can be particularly interesting to reduce the dose to the breasts, as well as tomotherapy when bulky disease. Proton therapy with the Bragg peak specificity can play a key role in limiting doses to organs at risk, when robust planning that will take into account geometric and physical uncertainties is available. The heterogeneity of Hodgkin lymphomas in terms of volume, shape and initial location are the key elements to take into account when choosing the preferred radiotherapy technique.
Collapse
Affiliation(s)
- A Boros
- Département de radiothérapie, Cancer campus Grand-Paris, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris Sud, université Paris Saclay, 94270 Le Kremlin-Bicêtre, France.
| | - V Ribrag
- Département d'hématologie, Cancer campus Grand-Paris, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Département des innovations thérapeutiques et essais précoces, Cancer campus Grand-Paris, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - É Deutsch
- Département de radiothérapie, Cancer campus Grand-Paris, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris Sud, université Paris Saclay, 94270 Le Kremlin-Bicêtre, France; U1030, Inserm, molecular radiotherapy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - C Chargari
- Département de radiothérapie, Cancer campus Grand-Paris, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris Sud, université Paris Saclay, 94270 Le Kremlin-Bicêtre, France; D19, institut de recherche biomédicale des armées, 91220 Brétigny-sur-Orge, France; Service de santé des armées, école du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France
| | - F Izar
- Département de radiothérapie, Institut universitaire du cancer de Toulouse, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France
| |
Collapse
|
39
|
Sall FB, Germini D, Kovina AP, Ribrag V, Wiels J, Toure AO, Iarovaia OV, Lipinski M, Vassetzky Y. Effect of Environmental Factors on Nuclear Organization and Transformation of Human B Lymphocytes. Biochemistry Moscow 2018; 83:402-410. [DOI: 10.1134/s0006297918040119] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
40
|
Saleh K, Michot J, Schernberg A, Danu A, Lazarovici J, Ghez D, Girinsky T, Khalife-Saleh N, Mazeron R, Ribrag V, Boros A. EP-1249: Repeated low-dose radiation therapy in indolent Non-Hodgkin Lymphoma patients. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31559-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Michot JM, Bouabdallah R, Doorduijn J, Vitolo U, Kersten M, Chiappella A, Zinzani P, Pourdehnad M, Nikolova Z, Ribrag V. CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Herin H, Castanon E, Dyevre V, Aspeslagh S, Marabelle A, Postel-Vinay S, Varga A, Gazzah A, Ribrag V, Bahleda R, Michot JM, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C. Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Ribrag V. Toward common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST? Ann Oncol 2017; 28:1409-1411. [PMID: 28472399 DOI: 10.1093/annonc/mdx209] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Indexed: 11/13/2022] Open
Affiliation(s)
- V Ribrag
- Drug Development Department (DITEP), Gustave Roussy Institut, Villejuif, France
| |
Collapse
|
44
|
Le Gouill S, Wermke M, Morschhauser F, Lim S, Salles G, Kloos I, de Burgat V, Becquart M, Paux G, Kraus-Berthier L, Pennaforte S, Stilgenbauer S, Walewski J, Ribrag V. A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_30] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | - M. Wermke
- Head Trial Management / Early Clinical Trial Unit; Universitätsklinikum Carl Gustav Carus; Dresden Germany
| | | | - S.T. Lim
- Division of Medical Oncology; National Cancer Centre; Singapore Singapore
| | - G. Salles
- Hematology; Hopital Lyon-Sud; Pierre-Bénite France
| | - I. Kloos
- Oncology; Servier; Suresnes France
| | | | | | - G. Paux
- Oncology; Servier; Suresnes France
| | | | | | | | - J. Walewski
- Lymphoid Malignancies; Maria Sklodowska-Curie Institute and Oncology Centre; Warsaw Poland
| | - V. Ribrag
- Hematology; Institut Gustave Roussy; Villejuif France
| |
Collapse
|
45
|
Blakemore S, Daigle S, McDonald A, Morschhauser F, Ribrag V, Salles G, McKay P, Tilly H, Schmitt A, Le Gouill S, Fruchart C, Radford J, Zinzani P, Assouline S, Cartron G, Dickinson M, Morin R, Wu H, Sausen M, Clawson A, Ho P, Miao H. PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_14] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | | | | | - F. Morschhauser
- Department of Hematology; Centre Hospitalier Universitaire; Lille France
| | - V. Ribrag
- Haematology; Gustave Roussy; Villejuif France
| | - G. Salles
- Hematology; Lyon-Sud Hospital Center; Pierre-Bénite France
| | - P. McKay
- Haematology; North Glasgow University Hospitals; Glasgow UK
| | - H. Tilly
- Hematology; Centre de lutte Contre le Cancer Henri Becquerel; Rouen France
| | - A. Schmitt
- Hematology; Institut Bergonié; Bordeaux France
| | - S. Le Gouill
- Service d'Hématologie Clinique; Universite De Nantes; Nantes France
| | - C. Fruchart
- Hematologie; Centre François Baclesse; Caen France
| | - J. Radford
- Molecular & Clinical Cancer Sciences (L5); The University of Manchester; Manchester UK
| | - P.L. Zinzani
- Hematology; University of Bologna; Bologna Italy
| | | | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | - M. Dickinson
- Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - R. Morin
- Molecular Biology and Biochemistry; Simon Fraser University; Burnaby BC Canada
| | - H. Wu
- Genomics and Oncology; Roche Molecular Systems; Pleasanton CA USA
| | - M. Sausen
- Research and Development; Personal Genome Diagnostics; Baltimore MD USA
| | - A. Clawson
- Biostatistics; Epizyme; Morrisville NC USA
| | - P.T. Ho
- Oncology Clinical Development; Epizyme; Cambridge MA USA
| | - H. Miao
- Oncology Clinical Development; Epizyme; Cambridge MA USA
| |
Collapse
|
46
|
Morschhauser F, Salles G, McKay P, Tilly H, Schmitt A, Gerecitano J, Johnson P, Le Gouill S, Dickinson M, Fruchart C, Lamy T, Chaidos A, Jurczak W, Opat S, Radford J, Zinzani P, Assouline S, Cartron G, Clawson A, Picazio N, Ribich S, Blakemore S, Larus J, Miao H, Ho P, Ribrag V. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_3] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- F. Morschhauser
- Department of Hematology; Centre Hospitalier Universitaire; Lille France
| | - G. Salles
- Hematology; Lyon-Sud Hospital Center; Pierre-Bénite France
| | - P. McKay
- Haematology; North Glasgow University Hospitals; Glasgow UK
| | - H. Tilly
- Hematology; Centre de lutte Contre le Cancer Henri Becquerel; Rouen France
| | - A. Schmitt
- Hematology; Institut Bergonié; Bordeaux France
| | - J. Gerecitano
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Johnson
- Medical Oncology; Southampton General Hospital; Southampton UK
| | - S. Le Gouill
- Service d'Hématologie Clinique; Universite De Nantes; Nantes France
| | - M.J. Dickinson
- Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - C. Fruchart
- Hematologie; Centre François Baclesse; Caen France
| | - T. Lamy
- Service d'Hématologie Clinique; CHU de Rennes; Rennes France
| | - A. Chaidos
- Haematology; Hammersmith Hospital; London UK
| | | | - S. Opat
- Clinical Haematology; Monash University; Clayton Australia
| | - J. Radford
- Molecular & Clinical Cancer Sciences (L5); The University of Manchester; Manchester UK
| | - P.L. Zinzani
- Hematology; University of Bologna; Bologna Italy
| | | | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | | | - N. Picazio
- Clinical Operations; Epizyme; Cambridge USA
| | - S. Ribich
- Biological Sciences; Epizyme; Cambridge USA
| | | | - J. Larus
- Clinical Data Sciences; Epizyme; Cambridge USA
| | - H. Miao
- Oncology Clinical Development; Epizyme; Cambridge USA
| | - P.T. Ho
- Oncology Clinical Development; Epizyme; Cambridge USA
| | - V. Ribrag
- Haematology; Gustave Roussy; Villejuif France
| |
Collapse
|
47
|
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker L, Salles G, Tilly H, Lamy T, Gressin R, Hermine O. Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_74] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | - C. Thieblemont
- Hemato-Oncologie, APHP, Hôpital Saint-Louis; Paris France
| | - L. Oberic
- Hématologie, IUCT Oncopole; Toulouse France
| | - A. Moreau
- Hématologie, CHU De Nantes; Nantes France
| | | | | | - G. Damaj
- Hématologie, CHU Caen; Caen France
| | | | | | | | | | | | - C. Haioun
- hématologie, CHU Creteil; Creteil France
| | | | | | - O. Tournilhac
- Hématologie, CHU Clermont-Ferrand; Clermont-Ferrand France
| | - K. Le Dû
- Hématologie, Clinique Victor Hugo; Le Mans France
| | | | - G. Cartron
- hématologie, CHU Montpellier; Montpellier France
| | | | - G. Salles
- Hématologie, AP-HL Lyon; Lyon France
| | - H. Tilly
- hématologie, Centre Becquerel; Rouen France
| | - T. Lamy
- Hématologie, CHU Rennes; Rennes France
| | - R. Gressin
- Hématologie, CHU Grenoble; Grenoble France
| | - O. Hermine
- Hématologie, AP-HP Necker Paris; Paris France
| |
Collapse
|
48
|
Zinzani P, Fanale M, Chen R, Armand P, Johnson N, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos T, Tomita A, von Tresckow B, Shipp M, Zhang Y, Balakumaran A, Moskowitz C. PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_125] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- P.L. Zinzani
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES); Institute of Hematology “L. e A. Seràgnoli,” University of Bologna; Bologna Italy
| | - M.A. Fanale
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - R. Chen
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope National Medical Center; Duarte USA
| | - P. Armand
- Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - N. Johnson
- Division of Hematology; Jewish General Hospital; Montreal Canada
| | - P. Brice
- Department of Hematologic Oncology; Hôpital Saint-Louis; Paris France
| | - J. Radford
- Division of Molecular & Clinical Cancer Sciences; The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester UK
| | - V. Ribrag
- Department of Haematological Cancer; Institut Gustave Roussy; Villejuif France
| | - D. Molin
- Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology; Uppsala University; Uppsala Sweden
| | - T.P. Vassilakopoulos
- Department of Haematology & Bone Marrow Transplantation; National and Kapodistrian University of Athens, Laikon General Hospital; Athens Greece
| | - A. Tomita
- Department of Hematology & Oncology; Nagoya University Graduate School of Medicine *Current affiliation: Fujita Health University School of Medicine, Toyoake, Japan; Nagoya Japan
| | - B. von Tresckow
- Department of Internal Medicine; University Hospital Cologne; Cologne Germany
| | - M.A. Shipp
- Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - Y. Zhang
- Department of Biostatistics; LDS Oncology, Merck & Co., Inc.; Kenilworth USA
| | - A. Balakumaran
- Department of Oncology Clinical Development; Merck & Co., Inc.; Kenilworth USA
| | - C.H. Moskowitz
- Department of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
49
|
Stamatoullas A, Ghesquières H, Quittet P, Morschhauser F, Ribrag V, Brice P. PHASE I/II STUDY OF BRENTUXIMAB VEDOTIN IN REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS TREATED BY CHEMOTHERAPY (ICE) IN SECOND LINE BEFORE AUTOLOGOUS TRANSPLANTATION. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Stamatoullas
- Hematology-INSERM U 1245; Centre Henri Becquerel; Rouen France
| | | | - P. Quittet
- Hematology; CHU Montpellier; Montpellier France
| | | | - V. Ribrag
- Chairman Hematological Multidisciplinary Committee and DITEP (Chief Molecular Therapeutics in Hematological Early Drug Development; Institut Gustave Roussy; Villejuif France
| | - P. Brice
- Hematology; APHP - Hôpital Saint Louis; Paris Cedex France
| |
Collapse
|
50
|
Ribrag V, Feugier P, Doorduijn J, Delfau-Larue M, Hermine O, Kluin-Nelemans H, Dasilva M, Lopez-Hernandez A, Walewski J, Szymczyk M, Pott C, Homburg C, Van der Velden V, Gameiro P, Garcia-Sanz R, Ladetto M, van Krieken H, Cabeçadas J, Rymkiewicz G, Klapper W, Hoster E, Le Gouill S, Dreyling M. MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK
ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND a RITUXIMAB-LENALIDOMIDE MAINTENANCE. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- V. Ribrag
- Hematology; Gustave Roussy Cancer Campus; Villejuif France
| | - P. Feugier
- Hematology; Hôpitaux De Brabois; Vandoeuvre-Les-Nancy France
| | - J. Doorduijn
- Hematology; Department of Hematology, Erasmus MC; Rotterdam Netherlands
| | - M. Delfau-Larue
- Hématologie et Immunologie Biologiques; GH Henri Mondor; Creteil France
| | - O. Hermine
- Hematology; Groupe Hospitalier : Hôpital Universitaire Necker-Enfants Malades; Paris France
| | - H. Kluin-Nelemans
- Department of Hematology; University Medical Center Groningen, University of Groningen; Groningen Netherlands
| | - M. Dasilva
- Serviço De Hematologia; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | | | - J. Walewski
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - M. Szymczyk
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - C. Pott
- Klinisch-Experimentelle Hämatologie; Universitätsklinikum Schleswig-Holstein; Kiel Germany
| | - C. Homburg
- Laboratoriumhoofd Immunocytologie; Sanquin Diagnostiek; Amsterdam Netherlands
| | - V. Van der Velden
- Hematology; Department of Hematology, Erasmus MC; Rotterdam Netherlands
| | - P. Gameiro
- Biologia Molecular Laboratório De Hemato-Oncologia; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | | | - M. Ladetto
- Hematology; Azienda Ospedaliera Nazionale SS.Antonio e Biagio e C. Arrigo; Alessandria Italy
| | - H. van Krieken
- Pathology; Radboud University Medical Center; Nijmegen Netherlands
| | - J. Cabeçadas
- Serviço De Anatomia Patológica; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | - G. Rymkiewicz
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - W. Klapper
- Institut Für Pathologie, Sektion Hämatopathologie und Lymphknotenregister; Universitätsklinikum Schleswig-Holstein, Campus Kiel; Kiel Germany
| | - E. Hoster
- Department of Medicine III; University Hospital of Munich; Munich Germany
| | - S. Le Gouill
- Service d'Hématologie; CHU de Nantes; Nantes France
| | - M. Dreyling
- Department of Medicine III; University Hospital of Munich; Munich Germany
| |
Collapse
|